EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination

Marlou J Jongkees iD, Daryl Geers, Kathryn S Hensley, Wesley Huisman iD, Corine H GeurtsvanKessel, Susanne Bogers, Lennert Gommers, Grigorios Papageorgiou, Simon P Jochems, Jan G den Hollander, Emile F Schippers, Heidi S M Ammerlaan und 18 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiac451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Marlou J Jongkees und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medi…. Hauptthemen laut MEDLINE: COVID-19, HIV Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw, Dutch Organization for Health Research and Development, Health∼Holland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders.

Methods

The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity.

Results

Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60–66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423–941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24–46) to 4317 BAU/mL (95% CI, 3275–5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed.

Conclusions

An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HIV InfectionsFemaleHumansMaleMiddle Aged2019-nCoV Vaccine mRNA-1273Ad26COVS1Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesProspective StudiesSARS-CoV-2VaccinationAged

Stichwörter der Autor:innen

COVID-19HIVSARS-CoV-2 vaccinesadditional dosenonresponder

Substanzen

2019-nCoV Vaccine mRNA-1273Ad26COVS1Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Department of Viroscience, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Department of Parasitology, Leiden University Centre for Infectious Diseases, Leiden University Medical Centre, Leiden, the Netherlands.
  • Department of Biostatistics, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands.
  • Department of Infectious Diseases, Leiden University Medical Centre, Leiden, the Netherlands.

ORCID-Profile: Marlou J Jongkees, Wesley Huisman

Förderung

  • ZonMw
  • Dutch Organization for Health Research and Development
  • Health∼Holland

Zitieren

APA

Jongkees, M. J., Geers, D., Hensley, K. S., Huisman, W., GeurtsvanKessel, C. H., Bogers, S., Gommers, L., Papageorgiou, G., Jochems, S. P., den Hollander, J. G., Schippers, E. F., Ammerlaan, H. S. M., Bierman, W. F. W., van der Valk, M., Berrevoets, M. A. H., Soetekouw, R., Langebeek, N., Bruns, A. H. W., Leyten, E. M. S., …, & Roukens, A. H. E. (2023). Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac451

Vancouver

Jongkees MJ, Geers D, Hensley KS, Huisman W, GeurtsvanKessel CH, Bogers S, et al. Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac451

BibTeX
@article{Jongkees2023,
  author = {Jongkees, Marlou J and Geers, Daryl and Hensley, Kathryn S and Huisman, Wesley and GeurtsvanKessel, Corine H and Bogers, Susanne and Gommers, Lennert and Papageorgiou, Grigorios and Jochems, Simon P and den Hollander, Jan G and Schippers, Emile F and Ammerlaan, Heidi S M and Bierman, Wouter F W and van der Valk, Marc and Berrevoets, Marvin A H and Soetekouw, Robert and Langebeek, Nienke and Bruns, Anke H W and Leyten, Eliane M S and Sigaloff, Kim C E and van Vonderen, Marit G A and Delsing, Corine E and Branger, Judith and Katsikis, Peter D and Mueller, Yvonne M and de Vries, Rory D and Rijnders, Bart J A and Brinkman, Kees and Rokx, Casper and Roukens, Anna H E},
  title = {Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiac451}
}
Kostenlos starten →